Moreover, considering these cases with an absence of a robust antibody response, the potentially protective role of CD8+ T cells emphasizes the importance of early vaccination against SARS-CoV-2 in cancer patients, with the aim to strengthen the virus-specific cellular immunity [11,12,13,14]. This evidence concerns the gene CD8A and cancer.